Lactulose for Liver Disease: How It Works and What to Expect

Lactulose is a synthetic sugar that your body cannot absorb, and that is precisely what makes it useful in liver disease. For more than fifty years it has been the first-line treatment for hepatic encephalopathy, a condition in which a failing liver allows toxins, especially ammonia, to build up and disrupt brain function.¹ The drug works through several overlapping actions in the gut, and the experience of taking it daily is shaped as much by its side effects and dosing quirks as by its clinical benefits.

What Lactulose Actually Does Inside the Gut

Because humans lack the enzyme to break lactulose down, it passes through the stomach and small intestine intact, drawing water into the bowel along the way. A randomized trial confirmed that lactulose substantially increases water content in the small bowel and speeds up gut motility within a few hours of a dose.² That explains the laxative effect, but the story in liver disease goes further.

When lactulose reaches the colon, resident bacteria ferment it into short-chain fatty acids, mainly acetate. This fermentation drops the pH of the colon’s contents, creating an acidic environment that converts ammonia (NH₃) into ammonium (NH₄⁺), a charged form that cannot cross back into the bloodstream. Classic radiotelemetry work showed that lactulose markedly acidifies the contents of the proximal colon, though the effect fades somewhat by the time contents reach the distal colon.³ The faster transit time then helps flush that trapped ammonium out of the body in stool. Between the acidification, the laxative purge, and the trapping of ammonia, lactulose lowers the amount of toxin reaching the brain.

More recent research has revealed a third dimension to the mechanism. Lactulose acts as a selective food source for beneficial bacteria, particularly bifidobacteria. A 2023 study in Nature Microbiology found that patients treated with lactulose had higher densities of intestinal bifidobacteria, which metabolize the drug into high concentrations of acetate. That combination of acetate production and luminal acidification reduced the growth of antibiotic-resistant bacteria in the gut, and patients on lactulose had fewer systemic infections and lower mortality.⁴ Separate work in patients with acute pancreatitis confirmed that lactulose enriched bifidobacterium populations while reducing pathogenic bacteria.⁵ So lactulose is not just flushing ammonia; it is reshaping the microbial neighborhood in ways that protect a vulnerable liver patient from infection.

Treating an Acute Episode of Hepatic Encephalopathy

Hepatic encephalopathy (HE) can range from subtle confusion and slowed reaction times to deep coma. When someone with cirrhosis shows up in the emergency department with overt HE, lactulose is typically the first medication given. Early controlled studies showed it was effective at resolving altered mental status, and it has been the standard of care ever since.⁶ The usual approach is to give oral doses every one to two hours until a bowel movement occurs, then adjust to maintain two to three soft stools per day.

One finding that sometimes surprises clinicians is that polyethylene glycol (PEG), the bowel-prep solution used before colonoscopies, may resolve acute episodes faster. In the HELP trial, about nine out of ten patients given PEG improved within 24 hours, compared with roughly half of those on standard lactulose therapy. The median time to HE resolution was one day with PEG versus two days with lactulose.⁷ A systematic review and meta-analysis confirmed that PEG leads to more rapid HE resolution in the first 24 hours and shorter hospital stays, without increasing side effects.⁸ Despite these results, PEG has not displaced lactulose as the default first-line agent in guidelines, partly because the evidence base is still smaller and partly because lactulose doubles as a long-term maintenance therapy once the acute crisis passes.

Minimal Hepatic Encephalopathy and Everyday Cognitive Function

Not every episode of HE is obvious. Many people with cirrhosis have what is called minimal hepatic encephalopathy, where standard neurological exams look normal but specialized cognitive tests reveal slowed processing, poor attention, or impaired coordination. The practical consequences are real: difficulty driving safely, reduced work performance, and diminished quality of life. Treatment of this subtle form can delay or prevent risky situations like automobile accidents.⁹

A controlled trial of lactulose in patients with minimal HE showed meaningful improvement. After three months, patients in the lactulose group had far fewer abnormal results on cognitive tests, dropping from an average of about 2.7 abnormal tests at baseline to fewer than 1, while untreated patients showed no change. Quality-of-life scores improved in parallel, and the improvement tracked directly with better cognitive performance.¹⁰ This is a quiet but important benefit of lactulose. People who feel mentally foggy but have never been told they have encephalopathy may still benefit if their doctor screens for it.

Preventing Recurrence After an Episode

Once someone has experienced an overt episode of HE, the risk of it happening again is high. Staying on lactulose long-term substantially reduces that risk. In an open-label randomized trial, about 20% of patients taking lactulose had a recurrence over a median follow-up of 14 months, compared with nearly 47% of those who stopped the drug.¹¹ A separate trial confirmed the finding, showing both lactulose and probiotics were effective for secondary prevention of HE in cirrhosis.¹²

The overall evidence supports long-term lactulose use for preventing OHE recurrence, and guidelines recommend it as the backbone of maintenance therapy.¹³ This is where adherence becomes critical, and where the drug’s side effects start to matter most, because taking lactulose consistently every day for months or years is harder than taking it for a few days during a hospital stay.

Adding Rifaximin to the Mix

Rifaximin is a non-absorbed antibiotic that works in the gut to reduce ammonia-producing bacteria. It is frequently added to lactulose after a second episode of overt HE. A meta-analysis of seven randomized trials involving over 800 patients found that the combination of rifaximin plus lactulose improved HE outcomes about 30% more often than lactulose alone, and cut the risk of death by roughly 40%.¹⁴ Prevention trials showed that the combination reduced HE recurrence, hospitalizations, and ammonia levels while improving quality of life compared with lactulose alone.¹⁵

The practical question for patients is usually whether they need rifaximin added. Guidelines generally recommend considering the combination after the second overt episode, rather than starting it right away. Rifaximin is substantially more expensive than lactulose, so most clinicians reserve it for patients who break through on lactulose alone. But the mortality benefit in the meta-analysis is hard to ignore, and there is growing consensus that earlier addition may be justified in patients who struggle with adherence to lactulose or who have other risk factors for recurrence.

Side Effects and the Challenge of Daily Dosing

The most common side effects of lactulose are exactly what you would expect from a medication that pulls water into the bowel and speeds up transit: diarrhea, bloating, gas, and abdominal cramps. These effects are dose-dependent and, in many patients, the whole point. The goal of maintenance therapy is two to three soft bowel movements per day. Too few, and ammonia levels creep up. Too many, and the patient risks dehydration and electrolyte problems.

The taste is another issue. Lactulose syrup is intensely sweet, almost cloying, and some patients find it nauseating over time. Mixing it with water, juice, or even coffee can help, and crystalline formulations exist as an alternative for those who cannot tolerate the liquid. The sweetness and gastrointestinal effects together make adherence a genuine problem. A systematic review of the economic burden of HE found that diarrhea, abdominal pain, and bloating from lactulose drove nonadherence, which in turn led to failure to titrate the drug properly. In one study, failure to titrate lactulose was a common cause of preventable rehospitalization within a month of discharge.¹⁶

This creates a frustrating loop. The side effects push people to take less lactulose, which causes HE to flare, which lands them back in the hospital. Working closely with a doctor or pharmacist to find the right dose, and being honest about how much you are actually taking, is one of the most impactful things a patient can do.

Hypernatremia and the Danger of Overdosing

Beyond the everyday nuisance of bloating and diarrhea, lactulose carries a more serious safety risk that is often under-appreciated: it can cause dangerously high sodium levels in the blood. As an osmotic cathartic, lactulose pulls more water than sodium into the stool, which can shrink the fluid volume in the body and concentrate sodium in the bloodstream.¹⁷ This is especially risky in hospitalized patients who are being given aggressive doses during an acute episode of HE.

A large recent study of over 6,700 patients admitted with cirrhosis found that among those hospitalized primarily for HE, about one in five developed elevated sodium levels, and 6% developed severe hypernatremia (sodium at or above 150). Patients who developed severe hypernatremia had been receiving more than double the average daily lactulose dose of matched controls, roughly 87 grams per day versus 38 grams. The mortality rate in this group was extremely high.¹⁸ This does not mean lactulose is inherently dangerous. It means that aggressive dosing, particularly during hospital stays, requires monitoring of sodium and fluid status. Excessive dosing can cause the very kind of metabolic derangement that worsens encephalopathy rather than improving it.¹

What About Blood Sugar in People With Diabetes

A common concern among patients with both cirrhosis and diabetes is whether the sugar content in lactulose will affect blood glucose control. Lactulose itself is not absorbed, but the manufacturing process creates small amounts of absorbable sugar impurities. A randomized trial directly addressed this question and found that at the standard maintenance dose of 20 grams per day, and even at a higher dose of 30 grams per day, lactulose did not meaningfully affect blood glucose levels in people with type 2 diabetes who were not on insulin.¹⁹ A review of the same evidence concluded that there is no need to adjust for carbohydrate impurities in lactulose at recommended doses when managing blood sugar.²⁰ The side effects at these doses were limited to the expected gastrointestinal symptoms. For most people with diabetes taking lactulose for liver disease, the sugar content is a non-issue at standard dosing.

Lactulose Use as a Marker of Disease Severity

One counterintuitive finding worth understanding is that large population studies show lactulose use is associated with higher mortality. A Danish nationwide cohort study of patients with alcohol-related liver cirrhosis found that those using lactulose had an adjusted hazard ratio for death of about 1.6 compared with non-users.²¹ This does not mean lactulose causes death. The researchers used lactulose prescriptions as a surrogate marker for the presence of hepatic encephalopathy, and HE itself signals advanced liver disease. People on lactulose are sicker to begin with. The drug is treating a condition that reflects late-stage liver failure, so the association with mortality reflects the underlying disease severity rather than any harm from the medication.

This distinction matters because patients sometimes encounter this kind of statistic online and worry that the treatment itself is dangerous. The evidence from randomized trials consistently shows that lactulose reduces HE episodes, improves cognition, and lowers the rate of hospitalization. The observational association with mortality is a classic example of confounding by indication: the people who get the drug are the ones who need it because they are already sicker.

How Lactulose Became the Standard

Lactulose was first used in 1957 as an ingredient in infant formula before its medical applications were recognized. It was eventually registered as a prescription drug for constipation and hepatic encephalopathy in many countries, and its food use was restricted.²² Despite being used for HE for more than half a century, the evidence base has always been somewhat unusual. The early controlled trials were small, and the drug became entrenched as the standard before the era of large multicenter randomized trials. That is partly why newer agents like PEG can show faster resolution of acute episodes without dislodging lactulose from guidelines: the sheer weight of clinical experience and familiarity with lactulose is hard to override with a handful of newer trials.

The more recent discovery that lactulose reshapes the gut microbiome, promotes bifidobacteria, and reduces systemic infections has added a new rationale beyond simple ammonia trapping.⁴ These findings have renewed interest in understanding exactly how the drug works and raised questions about whether its benefits extend to aspects of liver disease beyond encephalopathy. Animal research suggests lactulose may help reduce bacterial translocation from the gut into the bloodstream, a process that drives infection and inflammation in cirrhosis. Whether this translates into clinical endpoints in humans beyond what is already captured in infection and mortality data remains an open question.

Practical Tips for People Taking Lactulose

If you have been prescribed lactulose for liver disease, the single most important thing to know is that the dose needs to be titrated to your bowel habits, not taken as a fixed amount. The target is two to three soft bowel movements a day. Fewer than that suggests the dose is too low; watery diarrhea many times a day suggests it is too high and puts you at risk for dehydration and electrolyte problems.

Timing: Most people take lactulose two to three times daily, though the exact schedule depends on the dose your doctor sets. Splitting doses through the day keeps ammonia levels more stable than taking it all at once.
Palatability: The syrup can be mixed into cold drinks, yogurt, or even frozen into a slush. Crystalline powder dissolved in water is another option if the syrup’s sweetness is unbearable.
Hydration: Because lactulose pulls water into the gut, you need to drink more fluids than you otherwise would. Dehydration worsens both encephalopathy and the risk of high sodium levels.
Missed doses: Skipping doses, even for a day, can allow ammonia to climb. If the side effects are intolerable, talk to your provider about adjusting the dose or adding rifaximin rather than quietly cutting back.
Monitoring: Expect your doctor to check blood work regularly, including sodium and potassium levels, especially if your dose is on the higher side or if you are ill and at risk of dehydration.

The gap between how lactulose is prescribed and how patients actually take it at home remains one of the biggest obstacles to preventing HE readmissions. The drug works well when dosed correctly, but the side effects create a steady temptation to take less than prescribed, and the consequences of underdosing may not become obvious until the next encephalopathy episode lands someone back in the hospital.